South Asian Journal of Cancer最新文献

{"title":"Transanal Minimally Invasive Surgery for Rectal Cancer.","authors":"Sheikh Mohammad Taha Mustafa, Deepak Govil, Vijay Arora, V K Malik, Shivendra Singh, Avinash Saklani, Rajesh Bhojwani, Shyam Aggarwal, Purvish M Parikh, C Selvasekar, Saumitra Rawat","doi":"10.1055/s-0044-1801775","DOIUrl":"10.1055/s-0044-1801775","url":null,"abstract":"<p><p>Transanal minimally invasive surgery (TAMIS) is considered a standard of care in rectal cancers. Its advantage is that it is organ preserving. Its main role is in early-stage cancers limited to the rectum (T1N0M0). Regular follow-up with computed tomography scan imaging is required. When done correctly in the right patients, the recurrence rate of rectal cancer is less than 3%. TAMIS can also be used as a salvage operation in symptomatic high-risk patients who are unable to undergo or are unfit for transabdominal resection.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"263-266"},"PeriodicalIF":0.6,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Mesocolic Excision for Colon Cancer: The New Standard of Care?","authors":"Saumitra Rawat, Shyam Aggarwal, Purvish M Parikh, Adarsh Chaudhary, Manish Kumar, Mohit Sharma, Peush Sahni, Ramesh Ardhanari, R Pradeep, Amitabh Yadav, Suviraj John, C R Selvasekar","doi":"10.1055/s-0044-1801754","DOIUrl":"10.1055/s-0044-1801754","url":null,"abstract":"<p><p>Complete mesocolic excision (CME) for colorectal cancer builds on the success of total mesorectal excision (TME), the international gold standard for rectal cancer. In TME, removal of the primary tumor along with associated mesocolon and accompanying structures as single intact specimen allows in toto excision of all structures that could potentially lead to dissemination. Recent meta-analysis has confirmed that CME results in better disease-free survival (DFS) and overall survival (OS) rates. CME can be done in three ways-open, laparoscopic, and robotic-assisted. We conducted a survey to identify the real-world situation with the use of CME by surgical oncologists. A total of 116 responders shared their experiences and thoughts. The benefit of CME was primarily thought to be for both OS and DFS by 78/116 (67%). The majority of CMEs are being conducted by the open method (74/116; 64%). A total of 52/116 (45%) were of the opinion that 6 to 10 surgeries constitute the learning curve for new surgeons for this technique. Based on our survey results, as well as two recently published systematic reviews and meta-analysis, it is time to consider CME as one of the standards of care in colorectal surgery.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"251-258"},"PeriodicalIF":0.6,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid Biopsy and Colorectal Cancer.","authors":"Shyam Aggarwal, Anuradha Chougle, Vineet Talwar, Pragya Shukla, Nitesh Rohtagi, Amit Verma, Rajesh Pasricha, Bhawna Sirohi, Chaturbhuj Agarwal, Sunil Pasricha, R K Choudhary, Gautam Goyal","doi":"10.1055/s-0044-1801753","DOIUrl":"10.1055/s-0044-1801753","url":null,"abstract":"<p><p>The majority of patients with colorectal cancer (CRC) will ultimately develop metastasis. Identifying specific molecular characteristics in them can help optimize their management in a personalized manner. This requires a noninvasive method for frequent sampling. Liquid biopsy provides such an option that is gaining increasing importance in most tumor types. We present the current status of liquid biopsy in CRC with respect to early diagnosis in high-risk population, screening, follow-up of patients on treatment, early identification of progression, and value of serial sampling. We will also discuss the potential for liquid biopsy to help identify changes related to microbiota, specific tumor-causing bacteria, and testing for ribonucleic acid associated with exosomes.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"246-250"},"PeriodicalIF":0.6,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations.","authors":"Purvish M Parikh, Ankur Bahl, Gopal Sharma, Raja Pramanik, Jyoti Wadhwa, Peush Bajpai, Sunny Jandyal, A P Dubey, Aditya Sarin, Subash Chandra Dadhich, Avinash P Saklani, Ashok Kumar, Abhijit Chandra, Saumitra Rawat, C Selvasekar, Shyam Aggarwal","doi":"10.1055/s-0044-1791689","DOIUrl":"10.1055/s-0044-1791689","url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic CRC is considered as a heterogenous disease. Its management is therefore complex and dynamic. In order the give a ready reference to community oncologists, we developed this real world recommendations.</p><p><strong>Methods: </strong>A group of experts with academic background and real world experience in mCRC got together. We reviewed the current literature and the insights gained from our real world experience. Based on the same we put together these recommendations.</p><p><strong>Recommendations results: </strong>Molecular testing should be done wherever possible. Most of these patients will be treated with a palliative approach. Doublet chemotherapy is a long-standing standard of care. Triplet therapy may be offered where a more aggressive approach is indicated. Combination with anti -vascular endothelial growth factor antibodies and/or anti EGFR antibodies is also considered standard. In the first-line setting, pembrolizumab can be used for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumours; Left and right sided tumours are distinct entities. Combination of chemotherapy and targeted therapy is used as per individual patient and tumour characteristics.Oligometastatic disease can be approached with potentially curative intent. Cytoreductive surgery plus chemotherapy can be offered to selected patients with peritoneal only metastases. Stereotactic body radiation therapy can be used as local therapy for patients with oligometastatic liver only disease who cannot be taken up for surgery. New strategies include induction-maintenance chemotherapy and perioperative chemotherapy. All drugs/ regimen included as standard of care in the first line can also be used in subsequent lines. Specific targetable driver mutation tumours can be treated accordingly with their complementary biological therapy.</p><p><strong>Conclusion: </strong>Multidisciplinary team management and shared decision making are possible when patient and caregivers choose to become active participants.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"287-295"},"PeriodicalIF":0.6,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic Multivisceral Resection (RMVR) of the Pelvis for Locally Advanced Colorectal Carcinoma: Single Oncosurgical Center Experience.","authors":"M A Chamila Lakmal, Chelliah R Selvasekar, Shyam Aggarwal, Soumitra Rawat","doi":"10.1055/s-0044-1791561","DOIUrl":"10.1055/s-0044-1791561","url":null,"abstract":"<p><strong>Introduction: </strong>Locally advanced colorectal cancer management remains a challenge due to multiple reasons. Some of the major ones include the changes following the use of neoadjuvant radiotherapy and systemic anticancer treatment and previous abdominal surgery (including defunctioning stoma and related changes) and the proximity of structures close to the cancer. Robotic colorectal surgery for malignancy is rapidly evolving as a surgical technique in the management of colorectal cancers but its role in the management of locally advanced disease is not defined.</p><p><strong>Methods: </strong>This is a retrospective analysis of robotic colorectal surgery performed and captured in a prospective database. Patients who underwent multivisceral robotic colorectal surgery from 2012 to 2022 were included in this study. Robotic colorectal surgeries without multivisceral resections were excluded.</p><p><strong>Results: </strong>A total of 24 patients underwent robotic multivisceral resection (RMVR). This included 6 males and 17 females. The 17 females underwent posterior clearance, 5 males underwent abdominoperineal resection with seminal vesicle excision, and 1 male underwent total pelvic exenteration. Of the patients, 22 had neoadjuvant pelvic radiotherapy. Sixteen (66.7%) had past lower abdominal surgery (stoma). Preoperative tumor staging was T3 or T4 in 90%, and 80% had R0 resection. The median lymph node harvest was 15 (range 4-31). There was zero need for conversion to open surgery and zero 90-day mortality.</p><p><strong>Conclusion: </strong>RMVR is a safe approach for locally advanced colorectal cancer, with acceptable surgical clearance.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"259-262"},"PeriodicalIF":0.6,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young Onset Colorectal Cancer.","authors":"Shyam Aggarwal, Viraj Lavingiya, Vamshi Krishna, Prakash Chitalkar, Vikas Ostwal, Purvish M Parikh","doi":"10.1055/s-0044-1791225","DOIUrl":"10.1055/s-0044-1791225","url":null,"abstract":"","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"225-228"},"PeriodicalIF":0.6,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC).","authors":"Purvish M Parikh, Amish Vora, Rajan Yadav, Akhil Kapoor, Tarini Sahoo, Senthil Rajappa, Govind Babu Kanakashetty, M Vamshi Krishna, Ghanashyam Biswas, Ankur Bahl, Nikhil Ghadyalpatil, Thirumalairaj Raja, Jyoti Bajpai, Amol Akhade, Randeep Singh, Shyam Aggarwal, Maheboob Basade, S H Advani","doi":"10.1055/s-0044-1791768","DOIUrl":"10.1055/s-0044-1791768","url":null,"abstract":"<p><p>It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant therapy has improved, and so has the chance of cure. These consensus guidelines will ensure that the community oncologist will be able to take the right decision for their patient. The expert committee shares their real-world experience as well as the consensus voting results. Patients eligible for adjuvant therapy with CDK4/6 inhibitors should start that treatment at the earliest. Based on current published data, abemaciclib is the preferred CDK4/6 inhibitor that should be used in eligible patients (unless contraindicated). To ensure optimal dose intensity and adherence to treatment schedule, use of literature and patient information material can improves compliance. Treatment modification requires early reporting of adverse effects, a responsibility of the patient and caregiver (relatives).</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"45-52"},"PeriodicalIF":0.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India.","authors":"Nandini Devi Rajan, Abhilash Menon, Praveen Kumar Shenoy, Manuprasad Avaronnan, Sherin Shahana, Bindu Therayangalath","doi":"10.1055/s-0044-1791969","DOIUrl":"10.1055/s-0044-1791969","url":null,"abstract":"<p><p>One year of adjuvant trastuzumab is the standard of care for HER2-positive breast cancer. In low-middle income countries, delivery of 1-year trastuzumab is challenging due to significant financial burden. Evidence for shorter durations of adjuvant trastuzumab is gaining popularity in this regard. In this study, we compared the effectiveness and safety of 1 year versus shorter durations of adjuvant trastuzumab practiced in our center. In total, 312 patients were included in this analysis. The median age was 52 years. More than two-thirds of patients (67.6%) had stage 2 disease and majority were hormone-receptor-positive (62.5%). The median follow-up duration was 50 months. The 4-year disease-free survival was 97.3%. The 4-year disease-free survival for shorter durations of adjuvant trastuzumab was 98% compared with 96.7% in 1-year trastuzumab therapy group. In univariate analysis, stage at diagnosis was the only factor which had statistically significant association with disease-free survival. In multivariate analysis, none of the variables were found to be predictive of survival. Two patients (0.6%) had significant left ventricular ejection fraction decline. Shorter durations of adjuvant trastuzumab have comparable 4-year disease-free survival to standard 1-year therapy and is an alternative adjuvant treatment option for HER2-positive breast cancer patients in resource-limited settings.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"62-66"},"PeriodicalIF":0.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Image-Guided Biopsy in Nonpalpable Breast Lesions: A Study in the Sub-Himalayan Region of North India.","authors":"Surya Pratap Singh, Charu Smita Thakur, Sushma Makhaik, Shruti Thakur, Anupam Jhobta, Sumala Kapila, Neelam Sharma, Neeti Aggarwal","doi":"10.1055/s-0044-1792007","DOIUrl":"10.1055/s-0044-1792007","url":null,"abstract":"<p><strong>Background: </strong>Nonpalpable breast lesions pose a challenge in their early diagnosis. Image-guided biopsy is preferred in these cases so that a pathological diagnosis of breast carcinoma is reached timely for a better prognosis as the disease has an increased chance of successful outcome with early identification and treatment.</p><p><strong>Objective: </strong>The study aims at evaluating the role of stereotactic core needle biopsy (CNB) and percutaneous ultrasound-guided core needle biopsy (US-CNB) in diagnosing suspicious nonpalpable breast lesions.</p><p><strong>Methods: </strong>Our study included 35 patients with nonpalpable breast lesions and having a Breast Imaging Reporting and Data System (BI-RADS) risk assessment category IV or V on mammography or sonography. These 35 lesions were subjected to percutaneous image-guided (stereotactic or US) biopsy for histopathological analysis.</p><p><strong>Results: </strong>Out of a total of 35 cases, 17 were pathologically malignant (48.6%), with the most common subtype being invasive ductal carcinoma (82.3%). Twenty-nine cases underwent US-CNB, 16 (55.1%) of which were malignant and 13 (44.8%) were benign on histopathological evaluation (HPE). The remaining six cases, which on mammography showed no mass but suspicious malignant calcification only, were subjected to stereotactic CNB, out of which one (16.6%) was malignant and five (83.3%) were benign on HPE. Hence, the lesions visible on sonography were more likely to be malignant.</p><p><strong>Conclusion: </strong>Sonography and mammography play a complimentary role in detecting breast carcinoma. Percutaneous biopsy under image guidance can be used as an accurate diagnostic alternative to open surgical excisional biopsy to avoid diagnostic delay.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"53-61"},"PeriodicalIF":0.6,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC).","authors":"Purvish M Parikh, Ghanashyam Biswas, Nilesh Ashok Dhamne, Chetan Dilip Deshmukh, Sewanti Limaye, Ashish Singh, Hemant Malhotra, Viashsta Pankaj Maniar, Bhupendra Nath Kapur, Prasad V S S Sripada, Vikas Tulsidas Talreja, Poonam Patil, Suhas Vilasrao Agre, Amit Dilip Bhat, Priya Privadarshini Nayak, Arun Seshachalam, Boman Nariman Dhabhar, Ajay Sharma, Niraj N Bhatt, Pratap Kishore Das, Atul Sharma, Govind Babu Kanakasetty, Suresh Hariram Advani","doi":"10.1055/s-0044-1791783","DOIUrl":"10.1055/s-0044-1791783","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is the most common malignancy group in India and several other low- and middle-income countries. Currently, majority of the patients present in advanced stage where systemic therapy is standard of care. Multiple relapses are also not uncommon. Almost all HNSCC tumors have epidermal growth factor receptor (EGFR) overexpression, making an attractive target. Cetuximab is the most successful method to target EGFR in HNSCC. After decades of its use, it still is a prominent part of the current management guidelines. Since other agents have also been proven to be useful, we felt it was necessary to develop a real-world consensus guideline to help the decision-making process among the community oncologists. Our expert committee therefore put together currently available data, insights from their real-world clinical practice, and voted to arrive at a consensus. These consensus guidelines represent how cetuximab should be used today in the management of HNSCC.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"90-102"},"PeriodicalIF":0.6,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}